Log In Sign up
The largest database of trusted experimental protocols

Fluenz

Manufactured by AstraZeneca
Visit Supplier
Sourced in United Kingdom

Fluenz is a laboratory equipment product developed by AstraZeneca. It is a device used for the automated processing and analysis of biological samples. The core function of Fluenz is to streamline and standardize sample preparation and measurement procedures, improving the efficiency and consistency of laboratory workflows.

Automatically generated - may contain errors

Lab products found in correlation

Vaxigrip, by Sanofi (1 mentions) Influvac, by Abbott (1 mentions)

4 protocols using fluenz

1

Immune Profiling After Live Attenuated Influenza Vaccination in Children

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Fifty-five healthy children (3–17 years old) were recruited from the Otorhinolaryngology outpatient clinic at Haukeland University Hospital, Norway. Thirty-nine children (20 boys and 19 girls, median age 4 years) were immunized with the trivalent LAIV (Fluenz; AstraZeneca) in 2012–2013 at 3, 7, or 14 days before elective tonsillectomy. Controls consisted of age-matched unvaccinated children scheduled for tonsillectomy, providing a background comparison for postvaccination tonsillar responses (Figure 1). The study was approved by the Ethical Committee of Western-Norway and the Norwegian Medicines Agency (www.clinicaltrials.gov: NCT01866540). Demographics and inclusion and exclusion criteria for this trial have been published, and this work is a continuation of earlier findings to decipher the immune profiling after LAIV [13 (link)].
Mohn K.G., Brokstad K.A., Islam S., Oftung F., Tøndel C., Aarstad H.J, & Cox R.J. (2020). Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. The Journal of Infectious Diseases, 221(9), 1528-1537.
+ Open protocol
+ Expand
2

Trivalent Influenza Vaccine Comparison

Check if the same lab product or an alternative is used in the 5 most similar protocols
The trivalent seasonal IIV was either subunit (Influvac, Abbott Laboratories) or split-virion (Vaxigrip, Sanofi Pasteur) containing 15 μg HA per strain. The trivalent LAIV contained 107 fluorescent focus units (FFU) of each strain (FLUENZ, AstraZeneca). The A/H3N2 viruses changed between seasons from A/Perth/16/2009 in 2010-11 and 2011-12 to A/Victoria/361/2011 in 2012-13 and 2013-14.
Ertesvåg N.U., Cox R.J., Lartey S.L., Mohn K.G., Brokstad K.A, & Trieu M.C. (2022). Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses. NPJ Vaccines, 7, 67.
+ Open protocol
+ Expand
3

Influenza Vaccine Efficacy in Tonsillectomy Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols
Forty children (3–17 years old) and 37 adults (18–51 years old) were enrolled in the study after recruitment from the Ear-Nose-Throat outpatient clinic at Haukeland University Hospital, Norway. All subjects were patients scheduled for elective tonsillectomy due to chronic tonsillitis, tonsillar hypertrophy, or both but otherwise healthy. The study was approved by the Ethical Committee and the Medicines Agency. All participants or their guardians provided written informed consent before inclusion in the study (NCT01866540, www.clinicaltrials.gov).
Thirty-four children and 31 adults were vaccinated with trivalent LAIV (Fluenz; AstraZeneca) during the influenza season 2013–2014. The children and adults were divided into 3 groups and vaccinated on specific days before their scheduled tonsillectomy. Age- and gender-matched unvaccinated subjects (6 children and 6 adults) were enrolled as controls.
Lartey S., Zhou F., Brokstad K.A., Mohn K.G., Slettevoll S.A., Pathirana R.D, & Cox R.J. (2019). Live-Attenuated Influenza Vaccine Induces Tonsillar Follicular T Helper Cell Responses That Correlate With Antibody Induction. The Journal of Infectious Diseases, 221(1), 21-32.
+ Open protocol
+ Expand
4

Intranasal LAIV Immunization in Children and Adults

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Forty subjects (20 children (3–17 years old) and 20 adults (21–59 years old)) were intranasally immunized with 0.1 mL per nostril of the seasonal LAIV (Fluenz, Astra Zeneca, Liverpool, UK). LAIV (Fluenz) contained 107 fluorescent focus units (FFU) of A/California/7/2009(H1N1)pdm09-like and A/Victoria/361/2011(H3N2)-like strains in both 2012/13 and 2013/14 seasons, and either B/Wisconsin/1/209-like or B/Massachusetts/2/2012-like inFluenza B virus strains in the 2012/13 or 2013/14 seasons, respectively. The study was approved by the ethical and regulatory authorities (EUDRACT2012–002848-24, www.clinicaltrials.gov; ). Children received one (≥9 years old, n=6) or two doses (<9 years old, n=14) of LAIV in 2012 at a four-week interval, whereas adults received a single dose in 2013–14 season [5 (link)]. Blood samples were collected at day 0 (pre-vaccination), 28- and 56-days post-vaccination and plasma aliquoted and frozen for use in the serological assays, as previously described [28 (link)]. In children, cell preparation tubes (CPT, BD) were used to separate peripheral blood mononuclear cells (PBMCs) for the ELISpot assay.
Islam S., Zhou F., Lartey S., Mohn K.G., Krammer F., Cox R.J, & Brokstad K.A. (2019). Functional Immune Response to Influenza H1N1 in Children and Adults after Live Attenuated Influenza Virus Vaccination.. Scandinavian journal of immunology, 90(4), e12801.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!